PA
TBPH icon

Profund Advisors’s Theravance Biopharma TBPH Stock Holding History

Profund Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$173K Sell
10,171
-1,065
-9% -$17.6K ﹤0.01% 1114
2026
Q1 		$182K Buy
+11,236
New +$199K 0.01% 1041
2019
Q1 		– Sell
-8,352
Closed -$214K – 1241
2018
Q4 		$214K Sell
8,352
-3,682
-31% -$99.4K 0.01% 993
2018
Q3 		$393K Buy
+12,034
New +$328K 0.01% 991

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Profund Advisors's TBPH Position: Q2 2026 in Review

Profund Advisors reduced its Theravance Biopharma (TBPH) stake by 9.5% in Q2 2026, selling an estimated $17.6K and leaving 10,171 shares worth $173K. The position accounts for ﹤0.01% of the portfolio, ranked #1114.

Profund Advisors first reported a position in TBPH in Q3 2018 and has held it in 4 quarters since. The position peaked at $393K in Q3 2018. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Profund Advisors held 10,171 shares of Theravance Biopharma worth $173K as of Q2 2026.
  • Profund Advisors sold 1,065 Theravance Biopharma shares in Q2 2026, an estimated $17.6K.
  • Theravance Biopharma made up ﹤0.01% of Profund Advisors's portfolio in Q2 2026, its #1114 holding.
  • Profund Advisors first reported a position in Theravance Biopharma in Q3 2018 and has held it in 4 quarters since.
  • Profund Advisors's Theravance Biopharma position peaked at $393K in Q3 2018.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.